Insulin aspart, recombinant Subcutaneous and Nevirapine Extended Release
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Nevirapine Extended Release and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: nevirapine
Brand name: Viramune, Viramune XR
Synonyms: Nevirapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Nevirapine Extended-Release Tablets
- Insulin aspart, recombinant Subcutaneous-Nevirapine Oral Suspension
- Insulin aspart, recombinant Subcutaneous-Nevirapine Suspension
- Insulin aspart, recombinant Subcutaneous-Nevirapine Tablets
- Insulin aspart, recombinant Subcutaneous-New Day
- Insulin aspart, recombinant Subcutaneous-New Terocin
- Nevirapine Extended Release-Insulin degludec
- Nevirapine Extended Release-Insulin Degludec (U-100) Prefilled Pens
- Nevirapine Extended Release-Insulin Degludec (U-100) Vials
- Nevirapine Extended Release-Insulin Degludec (U-200) Prefilled Pens
- Nevirapine Extended Release-Insulin degludec and liraglutide
- Nevirapine Extended Release-Insulin degludec and liraglutide Subcutaneous